Aquestive Therapeutics, Inc.

$4.17+1.96%(+$0.08)
TickerSpark Score
50/100
Mixed
60
Valuation
60
Profitability
10
Growth
68
Health
50
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AQST research report →

52-Week Range37% of range
Low $2.22
Current $4.17
High $7.55

Companywww.aquestive.com

Aquestive Therapeutics, Inc. , a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

CEO
Daniel Barber
IPO
2018
Employees
142
HQ
Warren, NJ, US

Price Chart

+74.48% · this period
$7.49$4.88$2.27May 20Nov 18May 20

Valuation

Market Cap
$414.11M
P/E
-7.42
P/S
8.24
P/B
-15.01
EV/EBITDA
-7.89
Div Yield
0.00%

Profitability

Gross Margin
63.45%
Op Margin
-111.18%
Net Margin
-137.08%
ROE
190.87%
ROIC
-44.82%

Growth & Income

Revenue
$44.55M · -22.61%
Net Income
$-83,784,000 · -89.83%
EPS
$-0.76 · -49.02%
Op Income
$-69,650,279
FCF YoY
-47.54%

Performance & Tape

52W High
$7.55
52W Low
$2.22
50D MA
$4.15
200D MA
$4.87
Beta
1.50
Avg Volume
1.76M

Get TickerSpark's AI analysis on AQST

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
May 18, 26Zalewski Thomas A.other100,000
May 18, 26Zalewski Thomas A.other75,000
May 15, 26Barber Danielsell8,257
May 15, 26Cioffi Melinaother1,667
May 7, 26BRAENDER LORI Jother135,690
May 5, 26Boyd Peter E.other56,778
May 5, 26Barber Danielother335,922
May 5, 26TOTH A ERNEST JRother92,652
May 5, 26Jung Cassieother72,734
May 5, 26BRAENDER LORI Jother76,147

Our AQST Coverage

We haven't published any research on AQST yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate AQST Report →

Similar Companies